<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03173391</url>
  </required_header>
  <id_info>
    <org_study_id>HMM0301</org_study_id>
    <nct_id>NCT03173391</nct_id>
  </id_info>
  <brief_title>Long-term Efficacy and Safety of HMS5552 in T2DM</brief_title>
  <official_title>A 24-week Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of HMS5552 With Additional 28-week Open-label Treatment in T2DM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hua Medicine Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tigermed Consulting Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hua Medicine Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy and safety and population PK of HMS5552 as monotherapy in
      type 2 diabetic adult subjects, there will be 2 groups in the first 24 weeks, one group will
      receive HMS5552 , while the other group will receive placebo ; after 24 weeks, all subjects
      received HMS5552 for 28 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a phase III study in subjects with T2DM. As designed, the study will start with
      a 4-week, single-blind, placebo run-in period based on diet and exercise interventions for
      screening eligible subjects. The eligible subjects are randomly assigned to HMS5552 75mg BID
      group or placebo BID group with ratio 2:1 to receive a 24-week double-blind treatment. Then
      all subjects receive 28-week open-label treatment of HMS5552 75mg BID . After 52-week
      treatment, all investigational drugs should be discontinued and followed by 1-week for safety
      evaluation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 18, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in HbA1c</measure>
    <time_frame>24 weeks</time_frame>
    <description>The change of HbA1c from baseline in T2DM subjects after 24-week double-blind treatment
BID in combination with Metformin in T2DM subjects after 24-week double-blind treatment The change of HbA1c from baseline in T2DM subjects after 24-week double-blind treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change of 2-hour postprandial plasma glucose (2h-PPG) from baseline</measure>
    <time_frame>24 weeks</time_frame>
    <description>The change of 2-hour postprandial plasma glucose (2h-PPG) from baseline in T2DM subjects after 24-week doubleblind treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of fasting plasma glucose (FPG) from baseline</measure>
    <time_frame>24 weeks</time_frame>
    <description>The change of fasting plasma glucose (FPG) from baseline in T2DM subjects after 24-week double-blind treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with HbA1c &lt; 7.0%</measure>
    <time_frame>24 weeks</time_frame>
    <description>The HbA1c response rate in T2DM subjects after 24-week double-blind treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events over time</measure>
    <time_frame>52 weeks</time_frame>
    <description>including incidence of adverse events, incidence of hypoglycemic events, Physical examination, Vital signs, 12-lead ECG, clinical laboratory examination (blood routine, blood biochemistry and urine routine tests).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>HMS5552</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebos</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HMS5552</intervention_name>
    <description>BID Oral administration</description>
    <arm_group_label>HMS5552</arm_group_label>
    <other_name>Glucokinase Activator (GKA)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>BID Oral administration</description>
    <arm_group_label>Placebos</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, aged 18~75 years old

          2. naive T2DM 3.7.5% ≤ HbA1c ≤ 10.0% at screening 4.18.5 kg/m2 &lt; BMI &lt; 35.0 kg/m2 at
             screening;

        Exclusion Criteria:

          1. T1DM

          2. Fasting C-peptide &lt;1.0 ng/ml (0.33 nmol/L) at screening

          3. Medical history of Severe hypoglycemia,f diabetic ketoacidosis, diabetes lactic
             acidosis or hyperosmotic nonketotic diabetic coma, severe
             cardio-cerebrovascular,unstable or rapidly progressive kidney disease, Active liver
             diseases,diagnosed mental disease,etc
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dalong Zhu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yi Zhang, PhD</last_name>
    <phone>+8618502130980</phone>
    <email>yzhang@huamedicine.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hua Medicine Limited</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201203</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YI ZHANG, PhD</last_name>
      <phone>+86-021-58863005</phone>
      <email>yzhang@huamedicine.com</email>
    </contact>
    <investigator>
      <last_name>Dalong Zhu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2017</study_first_submitted>
  <study_first_submitted_qc>May 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2017</study_first_posted>
  <last_update_submitted>November 17, 2017</last_update_submitted>
  <last_update_submitted_qc>November 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GKA</keyword>
  <keyword>T2DM</keyword>
  <keyword>HMS5552</keyword>
  <keyword>mono therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

